Myricetin

Myricetin is a hexahydroxyflavone — the most heavily hydroxylated of the common dietary flavonols — and the pyrogallol B-ring is doing most of the work. That structural quirk makes the molecule simultaneously a strong radical scavenger, a promiscuous binder of ATP and kinase pockets, and an inhibitor of intestinal carbohydrate-hydrolyzing enzymes. The practical result is a flavonol that behaves less like a generic antioxidant and more like a soft, oral glucose disposal adjunct with a hepatoprotective side benefit.

Insulin-Mimetic Signalling and GLUT4 Translocation#

The mechanism most relevant to physique-focused users is myricetin's activation of the IRS-1 / PI3K / Akt cascade in skeletal muscle and adipocytes. By phosphorylating Akt in an insulin-like pattern, myricetin drives GLUT4 translocation to the sarcolemma, increasing glucose uptake into trained muscle independent of insulin concentration. It also activates AMPK in liver and adipose tissue, which shifts substrate handling toward oxidation and away from de novo lipogenesis.

"Myricetin exerts insulinomimetic effects through the activation of IRS-1/PI3K/Akt and AMPK pathways, supporting its use as an adjunct for glucose homeostasis." — Taheri Y, Suleria HAR, Martins N, et al., BMC Complementary Medicine and Therapies (2020)

Practically, this is why myricetin earns a slot in GDA stacks alongside berberine and R-ALA — the kinetics are slow, the effect size per gram is modest, but the mechanism is real and stacks additively with the other tier-1 GDA ingredients.

α-Glucosidase and α-Amylase Inhibition#

At the gut lumen, myricetin competitively inhibits intestinal α-glucosidase and pancreatic α-amylase, slowing the hydrolysis of complex carbs into absorbable monosaccharides. This blunts postprandial glucose excursions in OGTT and CGM data without producing the gas, bloating, and flatulence that make acarbose unpleasant.

"Myricetin supplementation significantly decreased fasting blood glucose, postprandial blood glucose, serum total cholesterol, and triglyceride levels in animal models." — Hou M, et al., PMC (2024)

For users running aggressive bulks or post-workout carb refeeds, this is the mechanism that shows up most visibly on a CGM trace — flatter spikes, faster return to baseline, less crash.

Nrf2 / HO-1 Antioxidant Defence and CYP2E1 Suppression#

Myricetin's hepatoprotective lane runs through upregulation of the Nrf2 / HO-1 antioxidant response element, paired with suppression of CYP2E1 — the cytochrome responsible for generating most of the reactive intermediates that drive 17α-alkylated oral toxicity, acetaminophen injury, and alcohol-induced lipid peroxidation.

"Myricetin ameliorates oxidative stress by enhancing the Nrf2/HO-1 pathway and inhibiting the production of pro-inflammatory mediators like TNF-α, IL-6, COX-2, and iNOS." — Imran M, et al., International Journal of Molecular Sciences (2025)

This is the basis for slotting myricetin into oral-cycle support stacks alongside TUDCA and NAC. It is not a substitute for either, but the antioxidant load takes some of the oxidative pressure off the hepatocytes during heavy oral exposure.

NF-κB Suppression and Inflammatory Cytokine Reduction#

Myricetin blunts NF-κB nuclear translocation, with downstream reductions in TNF-α, IL-6, COX-2, and iNOS across multiple tissue models (Imran et al. 2025; Semwal et al. 2016). The relevance is twofold: chronic low-grade inflammation is one of the upstream drivers of insulin resistance, so this mechanism reinforces the glucose-handling effects above, and the cytokine suppression contributes to the modest lipid and blood-pressure improvements seen in the polyphenol-stack literature.

CYP3A4, CYP2C9, and P-glycoprotein Inhibition#

This mechanism cuts both ways and deserves to be understood clearly. Myricetin inhibits CYP3A4 (IC₅₀ ≈ 7.8 µM), CYP2C9, and intestinal P-glycoprotein efflux. In rodent PK work, co-administration meaningfully raised exposure to a CYP3A4/2C9 substrate:

"Co-administration of myricetin significantly increased the AUC of losartan by 60.7% and the AUC of EXP-3174 by 31.1%, most likely due to the inhibition of CYP3A4, CYP2C9 and P-glycoprotein by myricetin." — Choi JS, Han HK, Journal of Pharmacy and Pharmacology (2010)

The upside: myricetin can modestly raise systemic exposure to co-administered polyphenols and some peptides/small molecules with poor baseline bioavailability. The downside: many compounds the bodybuilding and looksmaxxing community runs daily — tadalafil, sildenafil, finasteride, anastrozole, exemestane, most statins — are CYP3A4 substrates. Gram-range myricetin dosed alongside that stack can shift plasma levels in directions the user did not model. Spacing myricetin 4–6 hours from other oral drugs is the standard mitigation.

Direct Free-Radical Scavenging and Akt Protection#

Beyond Nrf2 induction, the six hydroxyl groups make myricetin a strong direct scavenger of superoxide and peroxynitrite. Peroxynitrite is the species that nitrates tyrosine residues on Akt, breaking insulin signalling under conditions of oxidative stress (high blood pressure, angiotensin II elevation, hyperglycemia). By neutralizing that ROS/RNS pressure, myricetin preserves Akt signalling and protects GLUT4 translocation in stressed myocytes — closing the loop on the insulin-sensitization mechanism above and explaining why the in vivo effects look larger than the modest direct kinase activity would predict.

Common (most users)#

• Mild GI upset (loose stools, nausea, abdominal fullness) at gram-range doses, especially on an empty stomach. Mitigation: dose with a meal, split the daily total across 2–3 feedings, or drop back to 500 mg/day for a week before titrating up.
• Yellow-tinted urine. Cosmetic only — flavonol conjugates excreted renally. No action needed.
• Mild postprandial hypoglycemia symptoms (lightheadedness, hunger, shakiness 60–90 min after a carb meal) when myricetin is layered on top of berberine, R-ALA, or metformin. Mitigation: ensure the carb meal is actually substantial; reduce one of the GDA stack components rather than all of them.
• Reduced iron or levothyroxine absorption — polyphenols chelate non-heme iron and bind thyroxine. Mitigation: separate myricetin from iron supplements and thyroid medication by at least 2–4 hours.

Uncommon (dose-dependent or individual)#

• CYP3A4 / CYP2C9 / P-gp–mediated drug interactions. Choi & Han (2010) showed co-administration with losartan raised parent-drug AUC by 60.7% and active metabolite AUC by 31.1% in rats:

"Co-administration of myricetin significantly increased the AUC of losartan by 60.7% and the AUC of EXP-3174 by 31.1%, most likely due to the inhibition of CYP3A4, CYP2C9 and P-glycoprotein by myricetin." — Choi & Han, J Pharm Pharmacol (2010)

This matters in stacks containing tadalafil, sildenafil, finasteride, anastrozole, exemestane, and most statins. Mitigation: space myricetin 4–6 h from CYP3A4 substrates, and if estradiol numbers or PDE5 response drift unexpectedly mid-cycle, the polyphenol load is the first variable to pull.

• Mild platelet-aggregation inhibition. Becomes noticeable when stacked with high-dose EPA/DHA, nattokinase, garlic extract, or aspirin. Watch for easier bruising, longer bleeding from shaving nicks, or nosebleeds in dry climates. Back off if any of those appear.
• Lipid-panel shifts. Usually favorable (modest LDL and triglyceride reductions in animal work — Hou et al. 2024), but worth tracking on an 8–12 week lipid panel in users running aggressive polyphenol stacks alongside oral AAS.
• Headache at 1,500 mg/day in caffeine-sensitive users — flavonols can potentiate the perceived stimulant load. Trim the dose or shift it away from the caffeine window.

Rare but serious#

• Clinically significant bleeding in users who combine multi-gram myricetin with therapeutic anticoagulants (warfarin, DOACs, clopidogrel). Warning signs: spontaneous bruising, gum bleeding, dark stool, prolonged bleeding from minor cuts. Discontinue immediately.
• Pronounced hypotension when myricetin substantially raises systemic exposure to tadalafil or losartan via CYP3A4 / CYP2C9 inhibition, particularly in users on cycle running tadalafil daily plus a polyphenol stack. Warning signs: orthostatic dizziness, exertional pre-syncope. Drop the myricetin first; do not stack-stack on top.
• Hepatic enzyme elevation has not been reported with myricetin itself — the molecule is hepatoprotective in CCl₄ and APAP models per Imran et al. (2025) — but the CYP-inhibition profile can functionally raise exposure to hepatotoxic co-administered compounds (oral 17α-alkylated AAS, high-dose acetaminophen). Elevated ALT/AST on cycle bloodwork should prompt a review of all CYP3A4 inhibitors in the stack, including myricetin.

Hard contraindications#

• Concurrent therapeutic anticoagulation (warfarin, DOACs, dual antiplatelet therapy). The additive bleeding risk is not worth the marginal metabolic benefit.
• Pre-surgical window. Discontinue at least 10–14 days prior to any planned surgical or significant dental procedure.
• Narrow-therapeutic-index CYP3A4 substrates taken in the same window — particularly cyclosporine, tacrolimus, and certain antiarrhythmics. Do not stack.
• Exogenous insulin protocols do not become safer with myricetin in the stack. GLUT4 sensitization is real, but it does not substitute for proper carb timing and dosing. Insulin + skipped meals + fasted training remains the hypoglycemia line that does not get crossed, regardless of GDA support.
• Levothyroxine and oral iron must be dosed at separate times from myricetin (≥2–4 h apart), not co-ingested.

Gender and PCT considerations#

Myricetin is non-hormonal — no HPTA suppression, no estrogenic or androgenic activity of practical significance, no aromatase impact worth modeling at oral supplement doses. Dosing is identical across the subject pool, and it is safe to continue uninterrupted through PCT, cruise, and off-cycle phases. The bleeding-risk and CYP-interaction caveats above apply equally to both sexes. No pregnancy data — standard precaution applies for users planning conception.